- Intractable epilepsy
- Terminally ill patients (Under legislation signed in 2018, a patient diagnosed with no more than six months to live may access cannabis-infused products produced by a state-licensed provider.)
PATIENT POSSESSION LIMITS
Cannabis extracts that contain more than 15 percent CBD and no more than 0.3 percent THC
No. However, legislation signed in 2018 seeks to permit the production and manufacturing of CBD-infused products to be sold at “cannabidiol-qualified pharmacies.” These products must contain a 10 to 1 ratio of CBD to THC and are only to be sold to patients who possess a doctor’s recommendation to use CBD. Separate legislation, also signed into law in 2018, permits the Department of Agriculture and Food to contract with a third party to cultivate cannabis for the purpose of manufacturing marijuana-infused oils and other related products. These products would be provided to terminally ill patients and also used in state-sponsored research trials.